logo-loader
viewAqualung Therapeutics

Aqualung seeking $15M in Series A funding to manufacture its drug to treat inflammatory diseases

Aqualung Therapeutics Corp CEO Dr "Skip" Garcia joined Proactive at the Biotech Showcase 2020 in San Francisco. The Arizona-based, privately-held early stage biotech company is involved in the treatment of inflammatory diseases, and is seeking $50M in Series A funding to manufacture its drug.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 6 hours ago

2 min read